Rudser Kyle D, de Boer Ian H, Dooley Annemarie, Young Bessie, Kestenbaum Bryan
Division of Biostatistics, Harborview Medical Center, University of Washington, Seattle, WA 98104-2499, USA.
J Am Soc Nephrol. 2007 Aug;18(8):2401-7. doi: 10.1681/ASN.2007010022. Epub 2007 Jul 18.
The impact of parathyroidectomy (PTX) on the long-term risks for hip and other fractures is unknown. Uncontrolled case series have reported an increase in bone mineral density after PTX. However, very low serum parathyroid hormone levels have been associated with decreased bone mineral density, adynamic bone disease, and fractures. This study compared long-term fracture rates among hemodialysis patients who underwent PTX with a matched control group. Data were obtained from the US Renal Data System. Patients who underwent a first PTX while receiving hemodialysis were matched with up to three control patients by age, race, gender, year of dialysis initiation, primary cause of renal failure, and the dosage of intravenous vitamin D used before PTX. Patients with a history of fracture or renal transplantation were excluded. Study outcomes were incident hip, vertebral, and distal radius-wrist fractures identified using hospitalization codes. Incident hip fracture rates in the PTX and matched control groups were 6.0 and 9.3 fractures per 1000 person-years, respectively. After adjustment, PTX was associated with a significant 32% lower risk for hip fracture (95% confidence interval 0.54 to 0.86; P = 0.001) and a 31% lower risk for any analyzed fracture (95% confidence interval 0.57 to 0.83; P < 0.001) compared with matched control subjects. Fracture risks were lower among hemodialysis patients who underwent PTX compared with matched control subjects. Surgical amelioration of secondary hyperparathyroidism may outweigh the risk of parathyroid hormone oversuppression in terms of bone health.
甲状旁腺切除术(PTX)对髋部及其他骨折长期风险的影响尚不清楚。非对照病例系列报告称PTX后骨矿物质密度有所增加。然而,极低的血清甲状旁腺激素水平与骨矿物质密度降低、骨动力缺乏性骨病及骨折有关。本研究比较了接受PTX的血液透析患者与匹配对照组的长期骨折发生率。数据来自美国肾脏数据系统。在接受血液透析时首次进行PTX的患者,根据年龄、种族、性别、透析起始年份、肾衰竭的主要病因以及PTX前使用的静脉注射维生素D剂量,与最多三名对照患者进行匹配。有骨折或肾移植病史的患者被排除。研究结局是使用住院编码确定的髋部、椎体和桡骨远端腕部骨折发生率。PTX组和匹配对照组的髋部骨折发生率分别为每1000人年6.0例和9.3例。调整后,与匹配对照组相比,PTX与髋部骨折风险显著降低32%(95%置信区间0.54至0.86;P = 0.001)以及任何分析骨折风险降低31%(95%置信区间0.57至0.83;P < 0.001)相关。与匹配对照组相比,接受PTX的血液透析患者骨折风险更低。就骨骼健康而言,继发性甲状旁腺功能亢进的手术改善可能超过甲状旁腺激素过度抑制的风险。